Lantheus Holdings, Inc. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: Other NEO average total compensation $6.83M.
- 2024-12-31: Other NEO average total compensation $4.20M.
- 2023-12-31: PEO total compensation $12.58M; PEO compensation actually paid $19.69M; Other NEO average total compensation $3.96M.
- 2022-12-31: PEO total compensation $9.48M; PEO compensation actually paid $21.04M; Other NEO average total compensation $2.97M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $6.83M | $1.94M | $493.33 | $99.29 | $234.00M | Net Revenue $1.54B | 2026-03-20 | |||
| 2024-12-31 | $4.20M | $7.58M | $663.16 | $94.19 | $312.00M | $1.53B | 2026-03-20 | |||
| 2023-12-31 | $12.58M | $19.69M | $3.96M | $4.74M | $459.60 | $89.48 | $327.00M | $1.30B | 2026-03-20 | |
| 2022-12-31 | $9.48M | $21.04M | $2.97M | $5.21M | $377.76 | $89.02 | $28.00M | $935.00M | 2026-03-20 | |
| 2021-12-31 | $6.19M | $14.89M | $1.57M | $2.16M | $214.16 | $111.35 | -$71.00M | $425.00M | 2026-03-20 | |
| 2024-12-31 | $4.20M | $7.58M | $436.18 | $122.71 | $312.40M | Net Revenue $1.53B | 2025-03-21 | |||
| 2023-12-31 | $12.58M | $19.69M | $3.96M | $4.74M | $302.29 | $116.57 | $326.70M | $1.30B | 2025-03-21 | |
| 2022-12-31 | $9.48M | $21.04M | $2.97M | $5.21M | $248.46 | $115.97 | $28.10M | $935.10M | 2025-03-21 | |
| 2021-12-31 | $6.19M | $14.89M | $1.57M | $2.16M | $140.86 | $145.06 | -$71.30M | $425.20M | 2025-03-21 | |
| 2020-12-31 | $4.33M | $300.59K | $1.11M | $601.96K | $65.77 | $130.27 | -$13.50M | $339.40M | 2025-03-21 | |
| 2023-12-31 | Mary Anne Heino | $12.58M | $19.69M | $3.96M | $4.74M | $302.29 | $116.57 | $326.70M | Net Revenue $1.30B | 2024-03-15 |
| 2022-12-31 | $9.48M | $21.04M | $2.97M | $5.21M | $248.46 | $115.97 | $28.10M | $935.10M | 2024-03-15 | |
| 2021-12-31 | $6.19M | $14.89M | $1.57M | $2.16M | $140.86 | $145.06 | -$71.30M | $425.20M | 2024-03-15 | |
| 2020-12-31 | $4.33M | $300.59K | $1.11M | $601.96K | $65.77 | $130.27 | -$13.50M | $339.40M | 2024-03-15 | |
| 2022-12-31 | Mary Anne Heino. | $9.48M | $21.04M | $2.97M | $5.21M | $102.60 | $248.46 | $28.10M | Net Revenue $935.10M | 2023-03-17 |
| 2021-12-31 | $6.19M | $14.89M | $1.57M | $2.16M | $139.26 | $140.86 | -$71.30M | $425.20M | 2023-03-17 | |
| 2020-12-31 | $4.33M | $300.59K | $1.11M | $601.96K | $131.54 | $65.77 | -$13.50M | $339.40M | 2023-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |